Articles tagged with Ovarian Cancer
Researchers at The Wistar Institute have found that ARID1A is essential for telomere cohesion, which helps maintain genomic stability. Inactivation of ARID1A leads to loss of telomere cohesion and selects against gross chromosome alterations.
A new study found that women who experienced PTSD symptoms were at a higher risk of developing ovarian cancer, particularly those with high-grade serous histotype. Researchers analyzed data from the Nurses' Health Study II and found a significant association between PTSD and increased ovarian cancer risk.
A new study links elevated levels of FAK to the survival of cancer stem cells and DNA repair in ovarian cancer tumors, making them resistant to platinum chemotherapy. Researchers found that FAK inhibition can improve treatment response in mice with chemo-resistant tumors.
The USPSTF recommends assessing risk in women with a history of breast, ovarian, fallopian tube, or peritoneal cancer, as well as those with an ancestry associated with BRCA1/2 mutations. Genetic counseling and testing are offered to those with a positive result after counseling.
A study at the George Washington University Cancer Center found a novel pathway causing platinum resistance in ovarian cancer cells. The ERK/PHD2/HIF-1α axis regulates HIF-1α stability, leading to poor prognoses for patients.
Women with BRCA1/2 gene mutations are at high risk of developing ovarian cancer, with a lifetime risk of 39-44% for BRCA1 and 11-17% for BRCA2. A new review provides guidance on screening, preventive surgery, contraception and management of menopausal symptoms to reduce this risk.
A combination of two FDA-approved drugs significantly extended the lives of mice injected with human ovarian cancer cells, altering the natural ratio of macrophages and improving survival. The treatment targets M1 macrophages, which can protect against tumor growth and progression.
Researchers will investigate loss of DNA repair mechanisms and secondary mutations leading to cancer. The goal is to develop improved cancer treatment regimens and predict drug efficacy.
Researchers at Houston Methodist and MD Anderson Cancer Center have found a new immunotherapy to treat ovarian and pancreatic cancers by blocking the action of MFAP5 protein. This protein promotes tumor growth and reduces survival rates in patients with these cancers.
Researchers at Penn State College of Medicine have identified a potential therapeutic target for high-grade serous ovarian cancer cells by preventing a protein from doing its job. Inhibiting this protein led to a halt in cell division and may be an effective strategy for future therapies.
The University of Colorado Cancer Center is enrolling patients in a Phase II clinical trial evaluating the effectiveness of Rucaparib, a PARP inhibitor, as maintenance therapy for endometrial cancer. The trial aims to determine the drug's ability to prevent cancer cell growth and death in patients with metastatic or recurrent disease.
Researchers at CRCHUM found that Ran protein is essential for ovarian cancer cells to migrate and invade healthy tissues. Inhibiting Ran expression can break down RhoA, a protein necessary for cell migration, leading to a loss of cancer cells' ability to move.
A new biomarker test developed by researchers at Uppsala University and Sahlgrenska Academy can detect women without cancer, reducing unnecessary surgery. The test has a high accuracy rate of one in three cases, increasing the detection of early stages and borderline cases.
A study by Columbia University researchers found that limiting ovarian cancer surgery to high-volume hospitals could improve survival but also reduce access for many rural and underserved patients. In fact, nearly 35% of low-volume hospitals had better-than-expected outcomes at 60 days and 51% at 2 years.
Researchers at University of Montreal Hospital Research Centre develop a two-step combination therapy to destroy cancer cells. They manipulate cellular aging to force cancer cells into senescence, then use senolysis to eliminate them. This strategy shows superior therapeutic effectiveness on ovarian cancer patients.
Researchers have identified eight protein biomarkers that enable accurate differentiation between endometrioid and high-grade serous ovarian carcinomas. This breakthrough could lead to more precise diagnosis and tailored treatment for patients, reducing the risk of undertreatment or overtreatment.
Researchers have successfully used circulating tumor DNA to monitor patient responses and find targeted treatments for ovarian cancer. The technique can detect genomic alterations in late-stage cancers, even when biopsies are difficult or impossible, and identify poor-responding patients after chemotherapy.
A recent clinical trial at the Stephenson Cancer Center found that patients with stage two, three, or four ovarian cancer can expect about 75 months of survival when their tumors are completely removed. The treatment regimen that caused fewer difficult side effects was just as effective as those with more severe side effects.
Researchers have identified 34 genes associated with an increased risk of developing the earliest stages of ovarian cancer. The study uses alternative splicing analysis to pinpoint these genes, which can help identify women at high risk and pave the way for new therapies.
Researchers at MIT have developed a novel fluorescence imaging system to improve surgery for ovarian cancer, enabling surgeons to detect and remove tumors as small as 0.3 millimeters. This technology has shown promising results in mice, with median survival rates 40% longer than those without image guidance.
A recent study found that fewer than a quarter of breast cancer patients and a third of ovarian cancer patients underwent genetic testing for cancer-associated mutations. The research, which analyzed data from over 83,000 women diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014, revealed substantial...
Researchers at the University of Manchester have identified a new class of drugs that can stop ovarian cancer cells from growing. The PARG inhibitors target weaknesses in DNA replication, making them sensitive to these treatments.
A new diagnostic tool has been developed to detect ovarian cancer earlier, with high sensitivity and specificity rates. The test uses liquid biopsy proteomics to identify unique protein signatures in uterine fluid, promising improved detection rates for young women at high risk of developing the disease.
A new experimental drug, 673A, targets and annihilates stem-like ovarian cancer cells that cause recurrence. The treatment, combined with chemotherapy, resulted in significantly greater survival rates in a mouse model of ovarian cancer.
Scientists at FAU create porous scaffolds using electrospinning to support ovarian follicle growth, showing promising results. The goal is to develop an ideal artificial ovary that mimics the natural environment for follicle maturity, potentially increasing fertility in cancer patients.
Researchers at the University of Kansas have developed a 'lab-on-a-chip' that can detect cancer in a minuscule amount of plasma, leading to timelier interventions and better outcomes for patients. The device uses a 3D nanoengineering method to mix and sense biological elements more efficiently, enabling faster and cheaper detection.
Researchers from the University of Sheffield discovered a compound that kills cancer cells without triggering apoptosis, making it resistant to treatment. The new drug lead is highly active against treatment-resistant cancers and may be particularly effective against ovarian cancer.
Researchers developed AI software that predicts ovarian cancer prognosis and treatment effectiveness, outperforming existing methods by up to four times. The technology can stratify patients based on CT scan texture differences, enabling personalized medicine.
A two-year study found that out of 1919 women diagnosed with non-cancerous ovarian cysts, 20% had the cysts disappear on their own, and 80% either resolved or didn't require intervention. The risk of complications from surgical removal was lower than previously thought.
Losartan reduces extracellular matrix content and solid stress in ovarian tumors, increasing blood supply and drug delivery. The addition of losartan to chemotherapy agents could improve outcomes for patients with ovarian cancer.
A new study describes a novel approach to suppressing chemotherapy-induced tumor growth and recurrence in ovarian cancer. Researchers developed an anti-inflammatory drug called PTUPB that blocks the release of tumor-promoting chemicals by macrophages.
Researchers discovered that ovarian cancer cells colonize the omentum after being caught in DNA 'webs' extruded by immune cells. Inhibiting NET formation reduces metastasis in mice, suggesting a new approach to limit ovarian cancer spread. This study provides insights into improving ovarian cancer treatment.
A new blood test has been developed to detect early stage ovarian cancer using a bacterial toxin, with the test detecting significant levels of cancer glycan in over 90% of women with stage 1 ovarian cancer. The test also showed 100% accuracy for later stages of the disease and has potential for simple liquid biopsy monitoring.
A new photoacoustic imaging technique may help diagnose ovarian cancer at an early stage, improving survival rates. The technology uses transvaginal ultrasound and co-registered photoacoustic tomography to reveal information about tumor angiogenesis and blood oxygen saturation.
A new study of over 72,000 women found that simple ovarian cysts are normal and extremely common, with no association to a higher risk of ovarian cancer. Simple cysts should be considered normal findings in women of any age and can be safely ignored unless symptomatic.
Researchers at the University of Arizona are working on a disposable falloposcope to detect early-stage ovarian cancer. The device aims to reduce unnecessary procedures and improve patient outcomes by providing accurate screenings for high-risk women.
A University of Guelph study has found that opening up the blood vessels to an ovarian tumour can potentially improve the effectiveness of treatment. By creating a healthy blood supply, the tumour becomes more accessible to treatment, increasing success rates.
A phase 3 SOLO-1 trial found that olaparib maintenance therapy significantly improved progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation. The median PFS for those who received olaparib was approximately three years longer than the placebo group.
A study of 178 countries found a strong negative correlation between family size and cancer incidence, with larger families having a protective effect against various types of cancer. The protective effects are stronger for males than females, with non-reproduction-related cancers also being involved.
Researchers found that cancer cells from the fallopian tube affect ovary's chemical signaling, leading to increased norepinephrine levels, which drive cancer cell migration. This study highlights the importance of understanding chemistry in ovarian cancer development and treatment protocols.
Researchers discovered that mutations in the ARID1A gene lead to a molecular switch in the SWI/SNF protein complex, causing an increase in BCL2 expression and promoting tumor cell survival. Inhibiting BCL2 using a small molecule inhibitor kills ovarian cancer cells resistant to EZH2 inhibition.
A new study found that daily low-dose aspirin use reduces the risk of ovarian cancer by 23 percent. In contrast, heavy use of non-aspirin NSAIDs increases the risk. The research analyzed data from over 200,000 women and confirms earlier findings about aspirin's role in reducing certain types of cancers.
A recent study published in JAMA Oncology found that low-dose aspirin (100mg or less) reduces the risk of ovarian cancer by 23% compared to non-users. Long-term heavy use of non-aspirin NSAIDs may increase this risk.
A new cancer vaccine targeting HER2 has demonstrated clinical benefits in a phase I clinical trial, with six out of eleven evaluable patients experiencing improvements in their condition. The vaccine provided complete or partial responses and stable disease in some cases.
Researchers identified subtle epigenetic differences that explain why some ovarian cancer patients respond to PARPi drugs, while others do not. The study adds to a vital checklist for matching patients with the right therapy for their cancer.
A large study published by The BMJ found that newer combined oral contraceptives are associated with a reduced risk of ovarian cancer in young women. The positive effect strengthens with longer periods of use and persists for several years after stopping, providing reassurance for women.
Research teams identified CT45 as an independent prognostic factor for patients with high-grade serous ovarian cancer. High levels of CT45 were associated with extended disease-free survival, with patients living up to 7.5 years longer than those without sufficient CT45.
A new clinical trial suggests that combining CTLA4 targeted therapy with PD-1 targeted therapy may improve treatment outcomes for women with recurrent epithelial ovarian cancer. The trial found improved tumor response proportions and progression-free survival hazard rates in patients treated with the combination therapy.
Researchers have analyzed nearly 4,000 mutations in the BRCA1 gene, shedding light on its role in breast and ovarian cancer. The findings provide immediate benefits to patients with previously inconclusive genetic test results, enabling clinicians to better interpret variant of uncertain significance.
Researchers found that rapidly spreading ovarian cancer cells recruit CAFs to accelerate cancer proliferation and spread by enhancing energy sources. Blocking glycogen mobilization could be a therapeutic strategy for reducing tumor dissemination.
Researchers at UVA are developing a new antibody-based approach that combines targeting two receptors on ovarian cancer cells to increase its effectiveness. The approach has shown promising results in lab tests, with antibodies being more than 100 times more effective than existing therapies.
A study by University of Colorado Anschutz Medical Campus found that doctors with personal cancer experience are 17% more likely to recommend ovarian cancer screening to low-risk women, despite guidelines against it. This bias may be due to overestimating a patient's risk and prioritizing their experience over evidence-based guidelines.
A recent study found that only 8% of disabled or older women who qualified for Medicare received BRCA1 and BRCA2 testing between 2000 and 2014. Women with these mutations are at higher risk for developing second breast cancer and ovarian cancer, making timely testing crucial for informed decision-making.
Researchers found that normal fallopian tubes can contain pre-cancerous cells that escape and later progress to cancer in the pelvic or abdominal cavity. This 'precursor escape' concept may help explain why some women present with advanced ovarian cancer beyond the fallopian tubes.
Researchers at Johns Hopkins and Insilico Medicine discovered novel epigenetically silenced genes in ovarian cancer, including methylation of the GULP1 gene. GULP1 expression is associated with late-stage disease and poor overall survival, suggesting its potential as a biomarker.
Researchers have discovered that women with low-grade serous ovarian cancer and a BRAF gene mutation experience excellent responses to BRAF inhibitor treatments. This finding is encouraging for patients who may not respond to conventional chemotherapy.
Researchers at Rockefeller University have discovered the molecular means by which some cancers caused by BRCA1 mutations evade treatment by PARP inhibitors. The study challenges previous assumptions about the mechanics of these drugs and provides a foundation for advancements in PARP inhibitor therapy.
A large population study from Denmark found no causal association between assisted reproduction treatment and increased risk of ovarian cancer. Female infertility, rather than ovarian stimulation, was associated with an increased risk of ovarian cancer.
Researchers at Mayo Clinic have discovered how the DNA repair protein 53BP1 relocates to chromosomes to fix damage, using RNA molecules as an off/on switch. This finding could lead to new therapies for ovarian cancer by targeting a specific protein called TIRR.
A study of 99,654 individuals found that lifetime light alcohol drinkers had the lowest combined risk of mortality or developing cancer. The risk increased linearly with lifetime alcohol consumption, with heavy and very heavy drinkers facing significantly higher risks.